At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
EP-1233 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of DNA Vaccine EP-1233 and Recombinant MVA-HIV Polytope Vaccine MVA-mBN32, Separately and in a Combined Prime-boost Regimen, When Given to Healthy, Vaccinia-naive, HIV-1-uninfected Adults
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jan 30, 2007·Updated Oct 14, 2021
In Brief
A Phase 1 clinical trial evaluating EP-1233 and MVA-mBN32 for HIV Infections. Completed, enrolled 36 participants across 3 sites.
Detailed Summary
The purpose of this study is to determine the safety of and immune response to two experimental vaccines, designed for use in combination, for the prevention of HIV infection in healthy adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
CollaboratorsHIV Vaccine Trials Network, Pharmexa-Epimmune, Bavarian Nordic
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2007
Enrollment StartApr 2007
Study CompletionAug 2008
TodayJul 2026
First PostedJan 30, 2007
Enrollment StartApr 1, 2007
Study CompletionAug 1, 2008
TodayJul 2, 2026
Posted 19.4 years ago
Interventions
EP-1233biological
DNA-HIV-recombinant vaccine
MVA-mBN32biological
HIV-recombinant viral vaccine